PAREXEL International Corporation (NASDAQ:PRXL) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Tuesday. The firm currently has a $98.00 target price on the medical research company’s stock. Zacks Investment Research‘s target price points to a potential upside of 11.81% from the stock’s current price.

According to Zacks, “Parexel International Corporation is one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., develops and offers a portfolio of innovative technology-based products and services that facilitate clinical drug development and are designed to decrease time to peak sales. “

Other analysts have also issued research reports about the company. Barclays PLC lowered PAREXEL International Corporation from an “overweighr” rating to an “equal weight” rating and set a $87.00 target price for the company. in a report on Tuesday, June 20th. Jefferies Group LLC restated a “hold” rating and issued a $88.10 target price on shares of PAREXEL International Corporation in a report on Wednesday, June 21st. Raymond James Financial, Inc. upgraded PAREXEL International Corporation from an “underperform” rating to a “mkt perform” rating in a report on Tuesday, June 20th. BidaskClub lowered PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Finally, Goldman Sachs Group, Inc. (The) upgraded PAREXEL International Corporation from a “sell” rating to a “neutral” rating and increased their target price for the company from $63.00 to $77.00 in a report on Tuesday, May 23rd. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $75.93.

Shares of PAREXEL International Corporation (PRXL) opened at 87.65 on Tuesday. The stock has a market cap of $4.45 billion, a P/E ratio of 38.53 and a beta of 0.79. The stock has a 50 day moving average price of $86.66 and a 200-day moving average price of $73.05. PAREXEL International Corporation has a 12 month low of $51.16 and a 12 month high of $87.86.

COPYRIGHT VIOLATION WARNING: This story was reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/08/08/parexel-international-corporation-prxl-upgraded-at-zacks-investment-research.html.

Institutional investors have recently bought and sold shares of the company. Quantbot Technologies LP increased its position in PAREXEL International Corporation by 644.3% in the second quarter. Quantbot Technologies LP now owns 1,630 shares of the medical research company’s stock valued at $102,000 after buying an additional 1,411 shares during the last quarter. Public Employees Retirement System of Ohio increased its position in PAREXEL International Corporation by 4.5% in the first quarter. Public Employees Retirement System of Ohio now owns 1,713 shares of the medical research company’s stock valued at $108,000 after buying an additional 73 shares during the last quarter. MSI Financial Services Inc increased its position in PAREXEL International Corporation by 17.4% in the third quarter. MSI Financial Services Inc now owns 1,690 shares of the medical research company’s stock valued at $117,000 after buying an additional 250 shares during the last quarter. Meadow Creek Investment Management LLC increased its position in PAREXEL International Corporation by 7.1% in the first quarter. Meadow Creek Investment Management LLC now owns 1,980 shares of the medical research company’s stock valued at $125,000 after buying an additional 132 shares during the last quarter. Finally, Invictus RG acquired a new position in PAREXEL International Corporation during the first quarter valued at approximately $158,000. 93.48% of the stock is currently owned by hedge funds and other institutional investors.

About PAREXEL International Corporation

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Get a free copy of the Zacks research report on PAREXEL International Corporation (PRXL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related companies with MarketBeat.com's FREE daily email newsletter.